Petrozziello, Tiziana
Bordt, Evan A.
Mills, Alexandra N.
Kim, Spencer E.
Sapp, Ellen
Devlin, Benjamin A.
Obeng-Marnu, Abigail A.
Farhan, Sali M. K.
Amaral, Ana C.
Dujardin, Simon
Dooley, Patrick M.
Henstridge, Christopher
Oakley, Derek H.
Neueder, Andreas
Hyman, Bradley T.
Spires-Jones, Tara L.
Bilbo, Staci D.
Vakili, Khashayar
Cudkowicz, Merit E.
Berry, James D.
DiFiglia, Marian
Silva, M. Catarina
Haggarty, Stephen J.
Sadri-Vakili, Ghazaleh http://orcid.org/0000-0003-3435-3544
Article History
Received: 11 June 2021
Accepted: 9 September 2021
First Online: 10 November 2021
Declarations
:
: The study was approved by the Mass General Brigham Healthcare Institutional Review Board (IRB).
: Written informed consent was obtained from all participants prior to study enrollment. Post-mortem consent was obtained from the appropriate representative (next of kin or health care proxy) prior to autopsy.
: Not applicable.
: B.T.H. is a member of Novartis, Dewpoint, and Cell Signaling Scientific Advisory Board (SAB), and of Biogen DMC, and acts as consultant for US DoJ, Takeda, Virgil, W20, and Seer; he receives grants from Abbvie, F prime, NIH, Tau consortium, Cure Alzheimer’s fund, Brightfocus, and JPB foundations. T.S.J. is on the scientific advisory board of Cognition Therapeutics and receives grant funding from European Research Council (grant 681181), UK Dementia Research Institute, MND Scotland, and Autifony. M.E.C. acts as consultant for Aclipse, Mt Pharma, Immunity Pharma Ltd., Orion, Anelixis, Cytokinetics, Biohaven, Wave, Takeda, Avexis, Revelasio, Pontifax, Biogen, Denali, Helixsmith, Sunovian, Disarm, ALS Pharma, RRD, Transposon, and Quralis, and as DSBM Chair for Lilly. J.D.B. has received personal fees from Biogen, Clene Nanomedicine and MT Pharma Holdings of America, and grant support from Alexion, Biogen, MT Pharma of America, Anelixis Therapeutics, Brainstorm Cell Therapeutics, Genentech, nQ Medical, NINDS, Muscular Dystrophy Association, ALS One, Amylyx Therapeutics, ALS Association, and ALS Finding a Cure. S.J.H. is or/has been a member of the SAB and equity holder in Rodin Therapeutics, Psy Therapeutics, Frequency Therapeutics, and Souvien Therapeutics, and has received consulting or speaking fees from Sunovion, Biogen, AstraZeneca, Amgen, Merck, Juvenescence, Regenacy Pharmaceuticals, and Syros Pharmaceuticals, and funding from F-Prime, Tau Consortium, Alzheimer’s Association/Rainwater Foundation Tau Pipeline Enabling Program and the Stuart & Suzanne Steele MGH Research Scholars Program. None of these had any influence over the current paper.